Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma
- First Posted Date
- 2024-04-17
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- Boehringer Ingelheim
- Registration Number
- NCT06370871
A Study in Healthy Men and Women to Test Whether BI 1569912 Influences the Amount of Repaglinide, Midazolam and Bupropion in the Blood
- Conditions
- Interventions
- First Posted Date
- 2024-04-16
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 18
- Registration Number
- NCT06367153
- Locations
- 🇧🇪
SGS Life Science Services - Clinical Research, Edegem, Belgium
A Study in Healthy People to See How Zongertinib is Taken up Into the Blood When Given as Tablets Made by Two Different Manufacturers
- First Posted Date
- 2024-04-11
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 56
- Registration Number
- NCT06360081
- Locations
- 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany
A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis
- Conditions
- Interventions
- First Posted Date
- 2024-04-11
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 230
- Registration Number
- NCT06360094
- Locations
- 🇯🇵
Kyushu University Hospital, Fukuoka, Fukuoka, Japan
🇯🇵Kanagawa Cardiovascular and Respiratory Center, Kanagawa, Yokohama, Japan
🇪🇸Hospital Virgen del Rocío, Sevilla, Spain
A Study to Test How Well Different Doses of BI 3034701 Are Tolerated by Healthy Men and People With Overweight or Obesity
- First Posted Date
- 2024-04-08
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 125
- Registration Number
- NCT06352437
- Locations
- 🇩🇪
Charité Research Organisation GmbH, Berlin, Germany
A Study to Test How BI 456906 is Taken up in the Blood of People With and Without Kidney Problems
- First Posted Date
- 2024-04-08
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 32
- Registration Number
- NCT06352411
- Locations
- 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany
🇩🇪CRS Clinical Research Services Kiel GmbH, Kiel, Germany
A Study in People With Overweight or Obesity to Test How BI 1820237, BI 456906, or a Combination of Both Affects Brain Activity
- Conditions
- Interventions
- First Posted Date
- 2024-04-08
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 23
- Registration Number
- NCT06352424
- Locations
- 🇩🇪
Charité Research Organisation GmbH, Berlin, Germany
A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
- Conditions
- Interventions
- First Posted Date
- 2024-03-28
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 300
- Registration Number
- NCT06335303
- Locations
- 🇨🇳
Affiliated Hospital, Xuzhou Medical college, Xuzhou, China
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸The Medical Research Group, Fresno, California, United States
A Study in Healthy People to Test How Well Different Doses of BI 3000202 Are Tolerated and How They Affect the Way the Body Handles Midazolam
- First Posted Date
- 2024-03-25
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 40
- Registration Number
- NCT06327256
- Locations
- 🇧🇪
SGS Life Science Services - Clinical Research, Edegem, Belgium
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib in Combination With Trastuzumab Deruxtecan or With Trastuzumab Emtansine and to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- First Posted Date
- 2024-03-21
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 240
- Registration Number
- NCT06324357
- Locations
- 🇧🇪
UZ Leuven, Leuven, Belgium
🇺🇸Valkyrie Clinical Trials, Los Angeles, California, United States
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, China